# Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

> **NCT02624063** · PHASE4 · COMPLETED · sponsor: **Federal University of São Paulo** · enrollment: 121 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Daclatasvir + Sofosbuvir
- **DRUG:** Simeprevir + Sofosbuvir

## Key facts

- **NCT ID:** NCT02624063
- **Lead sponsor:** Federal University of São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-03
- **Final completion:** 2017-05
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624063, "Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02624063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*